Sydnexis Announces FDA Acceptance of NDA for SYD-101 for the Treatment of Progression of Pediatric Myopia
Sydnexis announced that the FDA has accepted its new drug application (NDA) for SYD-101, which if approved would be the first and only pharmaceutical option for the treatment of progression of pediatric myopia in the United States. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 23, 2025.